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Abstract
 
Genetic lack of interleukin 12 receptor 
 
b
 
1 (IL-12R
 
b
 
1) surface expression predisposes to severe
infections by poorly pathogenic mycobacteria or 
 
Salmonella 
 
and causes strongly decreased, but
not completely abrogated, interferon (IFN)-
 
g
 
 production. To study IL-12R
 
b
 
1–independent
residual IFN-
 
g
 
 production, we have generated mycobacterium–specific T cell clones (TCCs)
from IL-12R
 
b
 
1–deficient individuals. All TCCs displayed a T helper type 1 phenotype and
the majority
 
 
 
responded to IL-12 by increased IFN-
 
g
 
 production and proliferative responses
upon activation. This response to IL-12 could be further augmented by exogenous IL-18. IL-
12R
 
b
 
2 was found to be normally expressed in the absence of IL-12R
 
b
 
1, and could be upreg-
ulated by IFN-
 
a
 
. Expression of IL-12R
 
b
 
2 alone, however, was insufficient to induce signal
transducer and activator of transcription (Stat)4 activation in response to IL-12, whereas IFN-
 
a
 
/IFN-
 
a
 
R ligation resulted in Stat4 activation in both control and IL-12R
 
b
 
1–deficient cells.
IL-12 failed to upregulate cell surface expression of IL-18R, integrin 
 
a
 
6, and IL-12R
 
b
 
2 on IL-
12R
 
b
 
1–deficient cells, whereas this was normal on control cells. IL-12–induced IFN-
 
g
 
 pro-
duction in IL-12R
 
b
 
1–deficient T cells could be inhibited by the p38 mitogen-activated pro-
tein kinase (MAP) kinase inhibitor SB203580 and the MAP kinase kinase (MEK) 1/2 inhibitor
U0126, suggesting involvement of MAP kinases in this alternative, Stat4-independent, IL-12
signaling pathway.
Collectively, these results indicate that IL-12 acts as a partial agonist in the absence of IL-
12R
 
b
 
1. Moreover, the results reveal the presence of a novel IL-12R
 
b
 
1/Stat4–independent
pathway of IL-12 responsiveness in activated human T cells involving MAP kinases. This path-
way is likely to play a role in the residual type 1 immunity in IL-12R
 
b
 
1 deficiency.
Key words: mycobacteria • Th1 • interleukin 12 (receptor) • interleukin 18 (receptor) • 
interferon-
 
g
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IL-12R
 
b
 
1–independent Pathway of IL-12 Responsiveness in Human T Cells
 
Introduction
 
The subdivision of CD4
 
1
 
 T lymphocytes into functionally
distinct subsets, based on their cytokine production profile,
has provided a basis for understanding the regulatory role of
T cells in intracellular infections, allergic manifestations,
and autoimmune diseases in both animals and humans (1–
5). Th1 cells producing IFN-
 
g
 
 and IL-2 are known to sus-
tain cell-mediated immunity against intracellular pathogens
by activation of microbicidal mechanisms in infected mac-
rophages. Th2 cells secrete IL-4 and IL-5, favoring allergic
responses and immunity to extra-cellular pathogens. A key
factor in human T cell differentiation is the presence of IL-
12 and IL-4; whereas IL-12 promotes the generation of
Th1 cells and additionally stimulates the growth and IFN-
 
g
 
production of T cells and NK cells (6, 7), IL-4 is the most
potent stimulus for Th2 differentiation (8).
Recently, several studies in humans have shown that ge-
netic deficiencies in type 1 cytokines (IL-12) or cytokine re-
ceptors (IL-12R
 
b
 
1, IFN-
 
g
 
RI, IFN-
 
g
 
RII) strongly affect
cell-mediated immunity–dependent resistance to mycobac-
teria and 
 
Salmonellae 
 
(9–11). Other groups and ours have
reported that IL-12R
 
b
 
1 deficiency, caused by deleterious
genetic mutations in the IL-12R
 
b
 
1 gene, causes a predispo-
sition to severe infections due to otherwise poorly patho-
genic mycobacteria or 
 
Salmonella
 
, and is associated with
strongly reduced, yet not fully abrogated IFN-
 
g
 
 production
by such patients’ PBMCs (9, 10). Interestingly, these pa-
tients did not develop unusual infections with other viral,
bacterial, or fungal pathogens, suggesting that IL-12R
 
b
 
1
deficiency may selectively cause a predisposition to severe
infections with certain intracellular bacteria. IL-12R
 
b
 
1–
deficient patients develop severe, yet mostly curable infec-
tions; in contrast, patients with complete IFN-
 
g
 
R deficien-
cies often develop fatal and treatment-resistant infections
(12, 13). This suggests that IFN-
 
g
 
/IFN-
 
g
 
R ligation is an
obligatory step towards immunity to intracellular pathogens
in humans, and that in IL-12R
 
b
 
1 deficiency low grade
(type 1) immunity to intracellular pathogens persists in the
absence of IL-12R
 
b
 
1. We have hypothesized that the ob-
served low production of IFN-
 
g
 
 in IL-12R
 
b
 
1 deficiency is
a key factor in controlling the residual type 1 immunity in
these patients (11), but the IL-12R
 
b
 
1–independent path-
way involved in this low IFN-
 
g
 
 remains unknown.
IL-12 binds with high affinity to heterodimeric IL-
12R
 
b
 
1/
 
b
 
2 complexes on T cells and NK cells (14–16). In
contrast to the IL-12R
 
b
 
1 chain, the human IL-12R
 
b
 
2
chain contains functional tyrosine-based signaling motifs in
its cytoplasmic domain (15, 16). The expression of the IL-
12R
 
b
 
2 chain is therefore thought to be a critical factor in
controlling T cell development and functioning. At
present, several lines of evidence suggest that IL-12/IL-
12R ligation signals through the Janus kinase (JAK)
 
1
 
–signal
 
tranducer and activator of transcription (Stat) signal trans-
duction pathway in both mice and humans (17–19). In par-
ticular, the essential role of Stat4 in IL-12R signaling has
been demonstrated in Stat4 knockout mice, in which IL-
12 induced IFN-
 
g
 
 production and proliferation of T cells
and NK cells were almost completely abrogated (20, 21).
Th1 cells can express both IL-12R subunits, but IL-12R
 
b
 
2
expression is lost in Th2 cells (22, 23), and consequently,
IL-12 induces tyrosine phosphorylation of JAK2 and Stat4
in human Th1, but not Th2 cells (22, 24). One factor that
is thought to contribute to the activity of IL-12 is IL-18,
which strongly amplifies IFN-
 
g
 
 production of T cells in re-
sponse to IL-12 (25).
Previous transfection studies have shown that IL-12 can
bind with low affinity to the independently expressed hu-
man IL-12R
 
b
 
2 chain when ectopically expressed in Ba/F3
or COS-7 cells, but a role for endogenous IL-12R
 
b
 
1 could
not be excluded (15, 16). Genetically IL-12R
 
b
 
1–deficient
patients provide a unique opportunity to investigate IL-
12R
 
b
 
2 expression and IL-12 functioning in the absence of
IL-12R
 
b
 
1. We have isolated mycobacterium (
 
myc
 
)
 
-
 
respon-
sive T cell clones (TCCs) from IL-12R
 
b
 
1–deficient pa-
tients and found that these cells display a Th1 phenotype
and respond to IL-12 by increased proliferative responses
and IFN-
 
g
 
 production upon activation. 
 
Materials and Methods
 
Patients
 
Patients (P1, P3, P4, and P17) presented with (recurrent) se-
vere mycobacterial and 
 
Salmonella
 
 infections in the absence of a
recognized immunodeficiency. All patients failed to express cell
surface IL-12R
 
b
 
1 due to individually different homozygous re-
cessive mutations or deletions in the IL-12R
 
b
 
1 gene, leading to
premature stop codons in the extracellular domain of the IL-
12R
 
b
 
1 molecule. Genetic mutations or deletions have been de-
scribed elsewhere for P1, P3 (9), and P4 (10). The genetic defi-
ciency in the IL-12R
 
b
 
1 gene of P17 was identified more recently
and will be described elsewhere. In brief, P1, a 27-yr-old female,
developed a severe 
 
Salmonella paratyphi
 
 sepsis at the age of 3 yr
and at the age of 22 yr presented with disseminated 
 
Mycobacterium
avium
 
 infection. P3 is a 4-yr-old female who developed progres-
sive 
 
Mycobacterium bovis
 
 BCG infection after vaccination at the age
of 1 yr, followed by severe 
 
Salmonella typhimurium
 
 sepsis at the age
of 2 yr. P4, a 31-yr-old man, suffered from a 
 
Salmonella enteritidis
 
infection at the ages of 11 and 20 yr and developed 
 
M
 
.
 
 avium 
 
in-
fection at the age of 24 yr. P17, a 5-yr-old boy, who has now
died, presented with disseminated BCG infection at the Hac-
ettepe University Children’s Hospital.
Generation and Cytokine Secretion Profile of Myc-responsive TCCs
To generate myc-responsive T cells, standard procedures were
used (26). PBMCs from P1 and P3 were stimulated with an M.
avium sonicate (2 mg/ml; Royal Tropical Institute) for 6 d, and fur-
ther expanded in the presence of 10 U/ml IL-2 (Proleukin; Chiron
Corp.) for another 7 d. Culture medium IMDM (Life Technolo-
gies) supplemented with 10% pooled heat-inactivated normal hu-
man serum (pooled screened serum from donors from The Neth-
1Abbreviations used in this paper: DTT, dithiothreitol; EMSA, electro-
phoretic mobility shift assay; ERK, extracellular signal–regulated kinase;
JAK, Janus kinase; MAP, mitogen-activated protein; MAPK, MAP ki-
nase; MEK, MAPK kinase; myc, mycobacterium; Stat, signal transducer
and activator of transcription; TCC, T cell clone. 519 Verhagen et al.
erlands), 100 IU/ml penicillin, and 100 mg/ml streptomycin (Life
Technologies). Expanding T cells were cloned in 96-well flat-bot-
tomed plates by limiting dilution in the presence of 105 irradiated
allogenic feeder cells from five random blood donors and M. avium
sonicate (2 mg/ml). After 10–17 d, individual TCCs were further
expanded in 24-well plates by standard mitogenic stimulation in
the presence of irradiated allogenic feeder cells and 0.5% PHA
(Murex Biotech Ltd.). After 3 d, 10 U/ml IL-2 was added to the
cultures. 10 d later, TCCs were screened for their responsiveness to
mycobacteria by testing 104 cells in 200 ml culture medium in a
flat-bottomed 96-well plate for 3 d in the presence of whole soni-
cated M. avium, Mycobacterium tuberculosis, or purified protein deri-
vate of M. tuberculosis (PPD, 2 mg/ml; Statens Serum Institute) in
the presence of irradiated PBMCs (5 3 104 cell/well) from an
HLA-matched donor. The cultures were incubated for an addi-
tional 16 h in the presence of [3H]thymidine (0.5 mCi/well). Cul-
tures were harvested and incorporated radioactivity was measured
by liquid scintillation counting. Control myc-responsive TCCs
(R1E4 and R2F10) generated from leprosy patients were used (1).
Cytokine production of TCC was tested at least 10 d after the
last restimulation. 105 cells were incubated in immobilized anti-
CD3 mAb (OKT3) and soluble PMA in a total volume of 200
ml/well in a flat-bottomed 96-well plate. From a panel of TCCs,
5 3 104 cells were incubated with M. avium sonicate (2 mg/ml) in
the presence of irradiated PBMCs (5 3 104 cell/well) from an
HLA-matched donor. Control TCCs were incubated with a My-
cobacterium leprae sonicate (5 mg/ml). After 24 h, 100 ml cell-free
supernatants were collected, pooled, and stored at 2208C until
testing. The remaining cultures were incubated for an additional
16 h in the presence of [3H]thymidine (0.5 mCi/well) to confirm
stimulation. The results are expressed as mean cpm of triplicate
cultures. Measurement of IFN-g and IL-4 concentrations in the
supernatants of stimulated or unstimulated TCCs was performed
with a specific solid-phase sandwich ELISA for IFN-g (Ucy-
Tech; University of Utrecht), and for IL-4 (The Central Labora-
tory of The Netherlands Red Cross Blood Transfusion Service).
Stimulation of TCCs with IL-12 and IL-18
10 d after the last restimulation, TCCs were tested for IL-12
and IL-18 responsiveness upon activation. 5 3 104 cells were cul-
tured in 200 ml culture medium in a flat-bottomed 96-well plate
for 72 h in the presence or absence of 5 U/ml IL-12 (a gift from
G. Trinchieri, Wistar Institute, Philadelphia, PA) or 2.5 ng/ml
IL-12 (R&D Systems), and/or different concentrations of IL-18
(0–100 ng/ml; Medical and Biological Laboratories Co.). T cells
were activated with M. avium sonicate (2 mg/ml) in the presence
of irradiated PBMCs (5 3 104 cell/well) from an HLA-matched
donor. Control TCCs were incubated with M. leprae sonicate (5
mg/ml). Mitogenic stimuli were soluble murine mAb to human
CD28 (CLB-CD28/1), three murine mAbs to human CD2
(CLB-T11/1, CLB-T11.2/1, Hic 27), and immobilized antiCD3
mAb. mAbs to CD28 and CD2 were a gift from R.A.W. van
Lier (The Central Laboratory of The Netherlands Red Cross
Blood Transfusion Service, Amsterdam, The Netherlands). After
72 h, supernatants were collected, pooled, and stored at 2208C
before determining IFN-g levels. During the last 16 h, the cul-
tures were incubated in the presence of 0.5 mCi/well [3H]thymi-
dine to determine proliferation. The results are expressed as mean
cpm of triplicate cultures.
Generation and Stimulation of PHA Blasts
PBMCs were isolated from heparinized blood by Ficoll-Ami-
dotrizoate density gradient centrifugation. Cells (106/ml) were
incubated in a 24-well plate in standard culture medium and 0.5%
PHA. After 3 d, the cells were expanded in the presence of 10
U/ml IL-2. PHA blasts (106 cells/ml) on day 10 after activation
were incubated in 24-well plates (Costar) with 1,000 U/ml IFN-a
(Pharma Biotechnologie Hannover) for 16 h or with 25 U/ml
IL-12 (Roche) for 20–24 h in the presence of 20 U/ml IL-2.
Cell Surface Staining
Cells (5 –20 3 104) were labeled with either FITC-conjugated
mouse mAb to CD3 (Becton Dickinson), unlabeled purified rat
anti–huIL-12Rb1 mAb (2B10, 1 mg/ml) (29), rat anti–huIL-
12b2 mAb (2B6, 1 mg/ml), mouse anti–huIL-18R (117-10C, 5
mg/ml) (30), FITC-conjugated mAb to a6-integrin (CD49f;
BD PharMingen), or isotype-matched control antibodies (BD
PharMingen) at 48C for 1 h. mAbs 2B10 and 2B6 were provided
by D. Presky (Department of Inflammation/Autoimmune Dis-
eases, Hoffmann-La Roche, Nutley, NJ). The cells labeled with
mAb 2B10, 2B6, or isotype control mAb were subsequently in-
cubated with biotinylated sheep anti–rat Ig (Amersham Pharma-
cia Biotech) for 30 min at 48C, followed by incubation with Avi-
din-FITC (1:500; Vector Laboratories) for 30 min. The cells
labeled with mAb 117-10C were subsequently incubated with
FITC-labeled anti–mouse IgM (Southern Biotechnology Associ-
ates Inc.) for 30 min. Cells were analyzed with a FACScan™
flow cytometer (Becton Dickinson).
Responsiveness of PHA Blasts to IL-12
PHA blasts were restimulated with irradiated allogenic adher-
ent cells. To z0.25–0.5 3 106 adherent cells, 1 3 106 PHA blasts
were added in 1 ml culture medium per well in a 24-well plate,
and incubated in the presence of 0.5% PHA and IL-2 (10 U/ml).
On day 3 after stimulation PHA blasts were collected, washed,
and tested for IL-12Rb1 and IL-12Rb2 expression (as described
above) and for responsiveness to IL-12 based on Stat4 activation.
Stat4 Activation
Cell Extracts. Total proteins were extracted from PHA blasts
(107 cells/ml) that were or were not exposed to 2.5 ng/ml IL-12
(R&D Systems) 1,000 U/ml IFN-a (Pharma Biotechnologie
Hannover), or control medium for 20 min. Cells were washed
with ice-cold PBS and packed cells were resuspended in 50 ml of
lysis buffer (20 mM Hepes/KOH [pH 7.9], 350 mM NaCl, 1 mM
MgCl2, 0.5 mM EDTA, 0.1 mM EGTA, 5 mM dithiothreitol
[DTT], 10 mg/ml aprotinin, 0.5% [vol/vol] of a saturated PMSF
solution in ethanol, 20% [vol/vol] glycerol, and 1% [vol/vol]
NP-40; Sigma-Aldrich). After 20 min incubation on ice, the ly-
sate was cleared by 15 min centrifugation at 14,000 g. The super-
natant was diluted with 1 vol of dilution buffer (20 mM Hepes/
KOH [pH 7.9], 0.2 mM EDTA, 2 mM DTT, 0.5% [vol/vol] of a
saturated PMSF solution in ethanol, 20% [vol/vol] glycerol, and
0.25% NP-40) to reduce salt concentration. The final protein
concentration was determined by Bradford microassay (Bio-Rad
Laboratories), using a calibrated BSA (Sigma-Aldrich) solution as
a reference.
Electrophoretic Mobility Shift Assay. All DNA binding reactions
were conducted in a final volume of 20 ml. The reactions were
started by adding 10 mg of total cell protein extract to a reaction
mixture containing 2 mg of poly-deoxyinosinic-deoxycytidylic
acid (Sigma-Aldrich), 2 mg of BSA, 2 ml of 103 binding buffer
(100 mM Tris-HCl [pH 7.5], 500 mM NaCl, 75 mM EDTA,
50% glycerol, and 2 mM DTT), 0.5% (vol/vol) of a saturated
PMSF solution in ethanol, 2 ml of dilution buffer (supplemented
with 100 mM KCl), and z10,000 cpm (6 0.1 ng) of the [g-32P]520 IL-12Rb1–independent Pathway of IL-12 Responsiveness in Human T Cells
ATP–labeled double-stranded DNA oligonucleotide. For super-
shift experiments, binding reactions were incubated with affinity-
purified rabbit anti–murine Stat4 (C-20; Santa Cruz Biotechnol-
ogy, Inc.) during the last 20 min of incubation. All reactions were
adjusted to the final volume of 20 ml with distilled water and in-
cubated for 30 min at room temperature. The whole sample was
then loaded on a 4% native polyacrylamide gel in 0.53 Tris-borate–
EDTA buffer. After electropheresis for 2 h at room temperature
at 10 V/cm, gels were dried, and separated protein–DNA com-
plexes were visualized by autoradiography using XAR5 films
(Eastman Kodak Co.).
Oligonucleotides. The following double-stranded DNA oligo-
nucleotides were used in electrophoretic mobility shift assay
(EMSA) analyses: FcgRI (59-AGCATGTTTCAAGGATTTGAG-
ATGTATTTCCCAGAAAAG-39), corresponding to the IFN-g
response region in the human FcgRI gene promoter (27), which
is bound by various STAT family members, including Stat4, and a
sequence (59-CCGGCCCCGCCCATCCCCGGCCCCGCCCA-
TCC-39) containing the herpes simplex virus SP-1 site. All oligo-
nucleotides were purchased from Biosource International and la-
beled by T4 polynucleotide kinase (Roche).
Inhibition of Mitogen-activated Protein Kinase Pathway
To assess the involvement of mitogen-activated protein kinases
(MAPKs) and MAPK kinases (MEKs) in IL-12–induced IFN-g
production in IL-12Rb1–deficient cells, myc-specific, mitogen-
treated TCCs were incubated with IL-12 in the absence or pres-
ence of the p38 MAPK inhibitor SB203580 (Sigma-Aldrich),
the mitogen-activated and extracellular signal–regulated kinase
MEK1/MEK2 inhibitor PD098059 (Sigma-Aldrich) or the
MEK1/MEK2 inhibitor U0126 (Promega). In brief, TCCs were
stimulated with anti-CD2 and anti-CD28 mAbs (see above) for
18 h before the addition of SB203580, PD098059, or U0126 to a fi-
nal concentration of 2.5, 25, and 2.5 mM, respectively. 30 min af-
ter addition of the inhibitors, TCCs were incubated for an addi-
tional period of 48 h, with or without exogenous IL-12.
Supernatants were harvested and IFN-g production was moni-
tored by ELISA.
Results
Type 1 Cytokine Secretion Profiles (IFN-g/IL-4) of TCCs
Generated from IL-12Rb1–deficient Patients. Since IL-12 is
known to be a key factor in Th1 cell development (6, 7), T
cell differentiation in IL-12Rb1 deficiency might be antici-
pated to be Th2 skewed. To study this, myc-specific TCCs
were generated from two IL-12Rb1–deficient individuals
with distinct recessive null mutations (P1 and P3), and cy-
tokine profiles of 25 myc-responsive TCCs were deter-
mined after standard stimulation with anti-CD3 mAb plus
PMA. All myc-responsive IL-12Rb1–deficient TCCs were
CD41CD82 and showed a clear Th1 phenotype, produc-
ing significant levels of IFN-g but low levels of IL-4
(shown in Table I for 10 representative TCCs, compared
with two control myc-responsive TCCs). Antigen-specific
stimulation of these TCCs induced similar cytokine profiles,
although lower levels of IFN-g tended to be produced.
To exclude the influence of skewing by microenviron-
mental cytokines possibly present during the generation of
TCCs, separate cloning experiments were performed by
direct limiting dilution of PHA-stimulated PBMCs from
P1 and P3. Cytokine secretion profiles of these TCCs
(with unknown specificity) were determined after mitoge-
nic stimulation. Also in these experiments TCCs with a
clear Th1 phenotype were observed (data not shown).
Myc-reactive Th1 TCCs from IL-12Rb1–deficient Patients
Can Still Respond to IL-12. Using the myc-responsive Th1
TCCs from genetically IL-12Rb1–deficient patients, we
next wanted to elucidate the pathway(s) involved in the re-
maining low IFN-g production that was previously ob-
served in PBMCs from these patients (9), and now also in
TCCs (this study). Since IL-12 is a key factor in Th1 acti-
vation, we first determined whether IL-12Rb1–deficient
Th1 TCCs were still capable of responding to IL-12. To
this end, IL-12Rb1–deficient Th1 TCCs (n 5 10) or IL-
12Rb1 wild-type (control) Th1 TCCs (n 5 2) were stimu-
lated independently with four different stimuli, in the pres-
ence or absence of exogenous IL-12, as indicated in Fig. 1.
TCCs were stimulated with antigen presented by HLA-
matched APCs (Fig. 1 A), or by mitogenic antibodies in
the absence of any added APCs, using either a mix of two
or three mAbs to CD2 (CD2d [Fig. 1, B and C] or CD2t
[Fig. 1 D], respectively) or a mAb to CD3 (Fig. 1 E) to
which in each case costimulatory anti-CD28 mAb was
added (Fig. 1, B–E) (28). All experiments were repeated
between two and seven times, and in each experiment
TCCs were stimulated by one to four of these different
stimuli (further details are given in the legend of Fig. 1).
Table I. Cytokine Secretion Profile of Myc-responsive TCCs from 
IL-12Rb1–deficient Patients
Antigen-specific
stimulation
Stimulation with
anti-CD3/PMA
TCCs IFN-g IL-4 IFN-g IL-4
Patients
S8A5 226 ,7 6,300 ,7
S3E8 554 25 109,915 54
S7C4 649 ,25 13,700 16
S8D3 1,119 ,25 6,827 33
K2B10 1,063 ,25 26,036 252
K8D1 426 8 31,400 4
K3F12 365 ,7 49,500 ,7
K8D10 2,129 ,7 26,400 ,7
K4D4 246 ,25 5,563 36
K2E9 4,559 23 2,900 154
Controls
R1E4 12,125 113 97,569 112
R2F10 1,449 30 88,868 1,244
10-d–rested TCCs from P1 (indicated by S), P3 (indicated by K), and
two control TCCs (R1E4 and R2F10) were stimulated with mycobacterial
sonicates (M. avium or M. leprae), or with CD3/PMA. 24-h supernatants
were then collected and analyzed for their IFN-g and IL-4 production
by ELISA. Data are given in pg/ml.521 Verhagen et al.
As shown in Fig. 1, IL-12 was found to induce a signifi-
cant response (defined as .50% increase in proliferation or
IFN-g production) in 8 out of the 10 tested IL-12Rb1–
deficient TCCs. The observed IL-12–induced responses were
consistent and reproducible, and representative experiments
are shown. The IL-12–mediated enhancement of prolifera-
tion and IFN-g production in the case of stimulation with
CD2d/CD28 (Fig. 1, B and C) or CD2t/CD28 (Fig. 1 D)
indicated a direct effect of IL-12 on IL-12Rb1–deficient T
cells in the absence of accessory cells. Although in some
cases these stimuli already induced relatively high levels of
IFN-g secretion, this could be further augmented by IL-12.
IL-12 also clearly enhanced the response of several IL-
12Rb1–deficient clones upon antigen-specific stimulation
(Fig. 1 A) or activation by CD3/CD28 mAbs (Fig. 1 E). 2
of the 10 IL-12Rb1–deficient TCCs (K4D8 and K3F12)
repeatedly did not respond to IL-12 upon any of the stimu-
lation modes used (Fig. 1, A–E), whereas the two IL-
12Rb1 wild-type control TCCs (R1E4 and R2F10) re-
sponded strongly to IL-12 as expected (Fig. 1, A–E).
Taken together, the results show that IL-12Rb1–defi-
cient patients are capable of developing Th1 T cells, and
that the majority of the Th1 TCCs are capable of respond-
ing to IL-12 in a specific and consistent fashion by en-
Figure 1. IL-12–enhanced pro-
liferative responses and IFN-g
production by myc-responsive
IL-12Rb1–deficient Th1 TCCs
and control TCCs upon activa-
tion. TCCs from P1 (filled sym-
bols), P3 (open symbols), and
control TCCs (symbols with
dashed lines) were stimulated in
the absence or presence of IL-12
with mycobacterial antigens and
APCs from HLA-matched do-
nors (A, showing proliferative
responses), with two mAbs to
CD2 and one mAb to CD28 (B
and C, showing IFN-g produc-
tion and proliferative responses,
respectively), with three mAbs to
CD2 and one mAb to CD28 (D,
showing IFN-g production) and
with one mAb to CD3 and one
mAb to CD28 (E, showing IFN-g
production). Proliferation exper-
iments shown in A and C were
always performed in triplicate.
The SD in these experiments did
not exceed 20%. All TCCs were
tested in two to seven indepen-
dent experiments, and in each
experiment, they were stimu-
lated by at least one to four of
the above described stimuli.
TCC S8A5 was tested in six in-
dependent experiments, TCC
S3E8 in five, TCC S8D3 in
three, TCC S7C4 in three, TCC
K8D1 in four, TCC K2E9 in
two, TCC K8D10 in three,
TCC K4D8 in two, TCC
K2B10 in three, and TCC
K3F12 in two independent ex-
periments. The control TCCs
R1E4 and R2F10 were tested in
five and three independent ex-
periments, respectively. The to-
tal number of stimulation assays
in which each of the different
TCCs was tested ranged from 7
to 19 (mean: 12.3).522 IL-12Rb1–independent Pathway of IL-12 Responsiveness in Human T Cells
hanced IFN-g production and/or proliferation. Thus,
these results reveal an IL-12Rb1–independent pathway of
IL-12 responsiveness in human T cells.
The IL-12–dependent Response of Myc-reactive, IL-12Rb1–
deficient Th1 TCCs Is Further Augmented by IL-18. Since
IL-18 is known to enhance IL-12–induced IFN-g produc-
tion in healthy individuals (25), we investigated the effect
of IL-18 on IL-12–induced IFN-g production also in IL-
12Rb1–deficient Th1 TCCs (n 5 7). Representative re-
sults of one out of three independent experiments are
shown in Fig. 2. In two IL-12Rb1–deficient TCCs (S8A5
and K2E9), IL-18 synergized with IL-12 in a dose-depen-
dent fashion by further increasing proliferation as well as
IFN-g production. A similar synergy was seen in control
TCCs (R1E4) although the levels of increased proliferation
and IFN-g production were higher. In a third IL-12Rb1–
deficient TCC (K8D10), the response to IL-12 and IL-18
was additive, and this TCC already responded to IL-18 in
the absence of IL-12. Thus, the IL-12–induced prolifera-
tion and IFN-g production of IL-12Rb1–deficient T cells
can be further augmented by IL-18.
Regulation of T Cell IL-12Rb2 Expression in the Absence of
IL-12Rb1. To further delineate this unexpected IL-12
responsiveness to IL-12Rb1 deficiency, we determined
surface expression of the IL-12Rb2 signaling chain on IL-
12Rb1–deficient and control TCCs. At the same time, we
studied the expression of the IL-18R that, in mice, has
been suggested to be selectively expressed on Th1 cells
(29). As can be seen in Fig. 3, PHA-stimulated IL-12Rb1–
deficient TCCs express IL-12Rb2 and IL-18R. The level
of expression differed among different TCCs, which may
correlate with the activation state (23) and the capacity of
the TCCs to respond to IL-12 and/or IL-18 as described
above. Control TCCs expressed both receptors.
To investigate the dynamics of IL-12Rb2 expression,
PHA-activated PBMCs (PHA blasts) from four IL-12Rb1–
deficient patients and four healthy controls were assayed at
different time points after stimulation (Fig. 4). No IL-
Figure 2. IL-18 further enhances IL-12–induced prolif-
erative responses and IFN-g production in myc-responsive
IL-12Rb1–deficient TCCs and control TCCs that were
mitogenically stimulated. Proliferative responses (A) and
IFN-g production (B) of TCCs from P1 (S8A5), P3
(K2E9, K8D10), and control TCCs (R1E4, R2F10) were
determined upon stimulation with two mAbs to CD2 and
one mAb to CD28 in the absence or presence of IL-12
and/or IL-18 for 72 h and subsequent 16-h incubation
with [3H]thymidine. R1E4 is representative for the results
with R2F10. Proliferation experiments were always per-
formed in triplicate, the SD of which did not exceed 20%.523 Verhagen et al.
12Rb1 expression could be detected on patient-derived
PHA blasts whereas control PHA blasts showed maximal
levels of IL-12Rb1 expression on day 3 after activation,
declining thereafter to baseline expression. In line with the
results in TCCs, PHA blasts from both patients and con-
trols showed equally strong IL-12Rb2 expression, which
was highest on day 3 after activation and declined to low or
undetectable levels on day 11 after activation. On day 3 af-
ter activation equal levels of IL-18R expression among pa-
tients and controls were seen (data not shown).
It has previously been reported that culturing T cells
with IL-12 or IFN-a upregulates surface expression of IL-
12Rb2 receptor in the absence of TCR stimulation (22).
Other molecules that have recently been described to be
upregulated by IL-12 are IL-18R and integrin a6 (30, 31).
To study the effect of IL-12 or IFN-a on IL-12Rb2 ex-
pression in IL-12Rb1 deficiency, PHA blasts of patients
and controls (10 d after activation) were incubated with IL-
12 or IFN-a for 20 and 16 h, respectively (23). Whereas
IFN-a upregulated the surface expression of IL-12Rb2
both in patients and in controls, exposure to IL-12 only in-
duced the expression of IL-12Rb2 on cells from healthy
controls, but not from patients (Fig. 5). Similarly, IL-12 in-
duced upregulation of IL-18R and integrin a6 expression
in controls, but not in patients (Fig. 6).
Taken together these results demonstrate that (a) human
IL-12Rb2 expression can occur normally in the absence of
IL-12Rb1 and can be upregulated by IFN-a independent
from IL-12Rb1; and (b) IL-12Rb2, IL-18R, and integrin
a6 expression can only be upregulated by IL-12 in the
presence of IL-12Rb1, suggesting that IL-12Rb2 expres-
sion alone is not sufficient to confer full IL-12 responsive-
ness to human T cells.
IL-12 Fails to Induce Stat4-containing Complexes in Human
IL-12Rb1 Deficiency. Since the IL-12Rb2 chain is essen-
tial in phosphorylating Stat4, a key signal transduction and
activator of transcription in IL-12–induced T cell responses
(17, 19–22), we investigated whether IL-12 signaling in IL-
12Rb2–expressing, IL-12Rb1–deficient T cells was in-
volved in Stat4 activation. Total cell extracts of 3-d PHA-
stimulated blasts of IL-12Rb1–deficient patients (n 5 4)
and healthy controls (n 5 2) that expressed optimum levels
of IL-12Rb2 (see above) were examined by EMSA for for-
mation of Stat4-containing complexes and binding to the
oligonucleotide probe FcgR1, which contains high affinity
binding sites for Stat4. As shown in Fig. 7 A, IL-12 in-
duced binding of the FcgR1 probe in the IL-12–responsive
PHA blasts from controls (lanes 11 and 14), but no activity
binding was found in cells from patients (lanes 2, 5, and 8).
As a positive control, IFN-a induced similar levels of Stat4
activation in samples from patients and controls (lanes 3, 6,
9, 12, and 15). Unstimulated samples were always negative
(lanes 1, 4, 7, 10, and 13). Competition analysis with unla-
Figure 3. IL-12Rb2 and IL-18R surface expression on mitogenically
stimulated myc-responsive IL-12Rb1–deficient TCCs and control TCCs.
TCCs from P1 (S3E9, S8A5), P3 (K2E9, K2B10), and control TCCs
(R1E4) were stimulated with PHA and adherent-irradiated feeder cells
for 72 h. Cell surface expression of IL-12Rb1 (left, thick lines), IL-
12Rb2 (left, dotted lines) and IL-18R (right, thick lines) were examined
by FACScan™ analysis. Isotype controls are presented by thin lines.
Figure 4. Representative examples of IL-12Rb2 surface expression on
PHA-stimulated PBMCs from IL-12Rb1–deficient patients and healthy
controls. PBMCs from IL-12Rb1–deficient patients (n 5 4) and controls
(n 5 4) were stimulated with PHA for 72 h, followed by subsequent in-
cubation in the presence of IL-2. Cell surface expression of IL-12Rb1
(thick lines) and IL-12Rb2 (dotted lines) were examined by FACScan™
analysis at different time points after activation. Isotype controls are pre-
sented by thin lines.524 IL-12Rb1–independent Pathway of IL-12 Responsiveness in Human T Cells
beled FcgR1 oligonucleotide (Fig. 7 B, lanes 1–3) indi-
cated the specificity of this DNA–protein interaction, and this
was further confirmed in supershift experiments showing
that Stat4-specific antiserum interfered with the formation of
IL-12–induced (Fig. 7 C, lane 8) as well as IFN-a–induced
(Fig. 7 C, lanes 6 and 10) protein–DNA complexes. As an
additional control for the quality of total cell extracts, no
differences were found between patient versus controls and
cytokine-stimulated versus unstimulated samples when
DNA binding activity of the constitutively expressed tran-
scription factor SP-1 to a specific SP-1 binding oligonucle-
otide was examined (data not shown).
Involvement of MAPKs in IL-12 Responsiveness in IL-
12Rb1–deficient T Cells. To assess the possible involve-
ment of MAPK signaling in the residual, Stat4-independent
IL-12 responsiveness in IL-12Rb1-deficient T cells, we
measured IL-12–induced IFN-g production in three TCCs
that were stimulated with anti-CD2/anti-CD28, either in
the presence or absence of the following inhibitors: the p38
stress MAPK inhibitor SB203580, the MEK1/2 inhibitor
PD098059, or the MEK1/2 inhibitor U0126. Whereas
SB203580 blocks p38 MAPK–mediated stress responses,
PD098059 and U0126 prohibit signaling via the extracellu-
lar signal-regulated kinase (ERK)/MAPK-mediated path-
way by interfering with the upstream MAPK kinases
MEK1/MEK2. Whereas U0126 inhibits the activated form
of MEK directly, PD098059 merely prohibits activation of
MEK by binding to its inactive form (32, 33). As shown in
Fig. 8, the IL-12–mediated enhancement of IFN-g pro-
duction was significantly reduced (z50%) in the presence
of SB203580 and U0126, but not PD098059, in the case of
TCCs S8D3 and S8A5. In clone S3E8 there was only
modest inhibition by SB203580 (20%), whereas U0126
again diminished IL-12–dependent IFN-g production over
50%. No effects of these inhibitors were observed on cell
viability, ruling out possibly toxic effects of these compo-
nents. Thus, these results imply a significant role for the
p38 MAPK, and the MEK1/2–p42 MAPK/ERK pathways
in residual IL-12 responsiveness and IFN-g production in
IL-12Rb1–deficient human T cells.
Discussion
The essential role of type 1 cytokines in protection
against intracellular pathogens is illustrated by the extreme
susceptibility of humans that are genetically deficient for
type 1 cytokines (IL-12p40) or type 1 cytokine receptors
(IL-12Rb1, IFN-gRI, IFN-gRII) to severe infections
with otherwise poorly pathogenic mycobacteria and Salmo-
Figure 6. IL-12 does not upregulate the surface expression of IL-18R
and integrin a6 on PHA-stimulated PBMCs from IL-12Rb1–deficient
patients compared with healthy controls. PBMCs from IL-12Rb1–defi-
cient patients (n 5 4) and controls were stimulated with PHA for 72 h,
followed by subsequent incubation in the presence of IL-2. At day 10 af-
ter activation, cells were incubated with IL-2 in the absence or presence
of IL-12 for another 20 h. Surface expression of IL-18R and integrin a6
were examined by FACScan™ and represented as mean fluorescence.
Figure 5. Representative examples of IL-12 or IFN-a upregulated ex-
pression of IL-12Rb2 surface expression on PHA-stimulated PBMCs
from IL-12Rb1–deficient patients and healthy controls. PBMCs from IL-
12Rb1–deficient patients (n 5 4) and controls (n 5 3) were stimulated
with PHA for 72 h, followed by subsequent incubation in the presence of
IL-2. At day 10 after activation, cells were incubated with IL-2 in the ab-
sence or presence of IL-12 or IFN-a for another 20 or 16 h, respectively.
Surface expression of IL-12Rb1 (thick lines) and IL-12Rb2 (dotted lines)
was examined by FACScan™. Isotype controls are presented by thin lines.525 Verhagen et al.
nella species (9–11). The different groups of genetic defi-
ciencies, however, are associated with important differ-
ences in clinical appearances and severity of the disease
outcome; while patients with complete IFN-gR deficien-
cies mostly develop fatal and treatment-resistant infections,
patients with IL-12Rb1 deficiency often develop less se-
vere and mostly curable infections (11). This suggests that
in IL-12Rb1 deficiency, low grade (type 1) immunity to
intracellular pathogens remains, independent of IL-12Rb1.
We have hypothesized that this may be due to the residual
low level of IFN-g production in these patients (9, 11), but
the pathway that controls this in the absence of functionally
competent IL-12R complexes remains obscure.
Since IL-12 is known to be a key factor in Th1 cell de-
velopment (6, 7), IL-12Rb1–deficient individuals might be
anticipated to be skewed towards a Th2 phenotype. Sur-
prisingly, all myc-responsive TCCs generated from IL-
12Rb1–deficient patients displayed a clear Th1 phenotype
based on cytokines secretion profiles (high IFN-g and low
IL-4). Thus, they do not differ qualitatively from the IL-
12R wild-type Th1 cytokine secretion profiles that were
described previously (1, 3, 4), although their quantitative
production of IFN-g is clearly diminished. Perhaps most
surprisingly, IL-12Rb1–deficient Th1 TCCs still re-
sponded to IL-12 when activated, leading to both cellular
proliferation and IFN-g production. This IL-12 respon-
siveness of IL-12Rb12/2 TCCs could be further aug-
mented by IL-18. Although the biological role of IL-18 in
humans is still largely unknown, a recent study showed a
role for IL-18 in type 1 immunity against M. leprae, sug-
gesting the involvement of IL-18 in mycobacterial immu-
nity (34). Our data thus implicate that IL-12, either alone
or together with IL-18, can regulate IL-12Rb1–indepen-
dent, low grade IFN-g production by Th1 T cells. This
low level of IFN-g production presumably is necessary and
sufficient to prohibit a fatal outcome of mycobacterial in-
fectious disease in IL-12Rb1–deficient patients.
This residual IL-12 response in IL-12Rb1 deficiency
compelled us to examine the expression and function of the
IL-12Rb2 signaling chain in the absence of the IL-12Rb1.
Previously, IL-12Rb2 was suggested to bind IL-12 in the
absence of IL-12Rb1 (14–16). In support of this suggestion,
Ba/F3 cells expressing the huIL-12Rb2 subunit alone
bound IL-12 with low affinity and proliferated in response
to IL-12 (14, 35). In these studies, however, a role for en-
dogenous IL-12Rb1 could not be excluded. To our
knowledge, our results are the first to show that in humans
IL-12Rb2 can be expressed at the cell surface in the absence
of IL-12Rb1 and that this expression can be upregulated by
IFN-a. The expression of IL-12Rb2 as well as IL-18R on
IL-12Rb12/2 TCCs is in line with their observed Th1
phenotype, since both receptors have been described to be
selectively expressed by Th1, but not Th2 T cells (23, 29).
Although IL-12Rb2–expressing IL-12Rb12/2 T cells
responded to IL-12 in the presence of antigens or mitoge-
nic stimuli, IL-12 alone failed to induce upregulation of
cell surface expression of IL-12Rb2, IL-18R, and integrin
a6, and failed to induce Stat4 activation, whereas in con-
Figure 8. Inhibitors of MAPK
signaling SB203580 and U0126
inhibit IL-12–enhanced IFN-g
production by IL-12Rb1–defi-
cient cells. Myc-specific TCCs
were stimulated with anti-CD2/
anti-CD28 for 18 h. Sub-
sequently, cells were pre-
treated for 30 min with either
the p38 MAPK–specific inhibi-
tor SB203580, the MEK1/
MEK2 (inactive form) inhibitor
PD098059, or the MEK1/2 (ac-
tive form) inhibitor U0126, be-
fore addition of IL-12. Control
cultures were treated identically
with mitogenic stimuli and in-
hibitors, but without addition of
IL-12. After 48 h, IFN-g secre-
tion was measured by ELISA.
Shown are control-corrected
values of IFN-g (in Dpg/ml),
representing the effect of inhibit-
ing MAPK signaling on IL-12–
enhanced IFN-g secretion in IL-
12Rb1 deficiency. Figure 7. IL-12 fails to induce DNA binding of Stat4-containing com-
plexes in IL-12Rb1–deficient patients. PHA-activated PBMCs were (1)
or were not (2) stimulated with IL-12 or IFN-a for 20 min. (A) Total
cell extracts were examined by EMSA for formation of Stat4-containing
complexes and binding to a labeled FcgR1 oligonucleotide. The arrow
indicates the DNA–Stat4 complexes. (B) Competition analysis (Comp.)
using unlabeled FcgR1 oligonucleotide (2.5, 5, or 250 times the amount
of labeled FcgR1 oligonucleotide) indicated the specificity of this DNA–
Stat4 interaction. (C) Supershift experiments were performed using Stat4-
specific antiserum that interfered with the formation of IL-12– and IFN-
a–induced DNA–Stat4 complex.526 IL-12Rb1–independent Pathway of IL-12 Responsiveness in Human T Cells
trol cells all these markers of IL-12R signaling were
present. Since several Stat4 binding sites have been identi-
fied on the IL-12Rb2 promotor (36), the absence of IL-
12–induced Stat4 activation in our patients may directly
account for the lack of IL-12–induced upregulation of IL-
12Rb2. A similar explanation may account for the lack of
IL-12–induced upregulation of IL-18R or integrin a6 ex-
pression. Although IL-12 activates multiple Stats (Stat1,
Stat3, Stat4, and Stat5 [17, 19, 37]), the essential role of
Stat4 in IL-12/IL-12R–induced signal transduction was
demonstrated in Stat4 knockout mice that showed strongly
reduced IL-12–dependent IFN-g production and cellular
proliferative responses in T cells and NK cells (20, 21).
Furthermore, the selective expression of the IL-12Rb2
chain on human Th1, but not Th2 cells has been shown to
correlate with the capacity of IL-12 to induce activation of
Stat4 in Th1, but not Th2 cells (22, 24). Here, however,
we clearly show that in humans IL-12Rb1 expression is
also necessary for IL-12–dependent Stat4 activation. Taken
together, our results show that IL-12 acts as a partial agonist
in IL-12Rb1 deficiency, inducing IFN-g production and
proliferation by activated T cells, whereas IL-12 alone
failed to activate Stat4 and to upregulate expression of IL-
12Rb2, IL-18R, or integrin a6 to detectable levels.
Several lines of evidence have pointed to IL-12–trig-
gered intracellular signaling pathways that are independent
of Stat4. First, it has been shown that the cytoplasmic re-
gion of huIL-12Rb2 could associate with JAK2, and that
IL-12–induced JAK2 activation correlated with Stat5
phosphorylation and cellular proliferation, whereas huIL-
12Rb1 interacted directly with TYK2, and IL-12–induced
activation of TYK2 correlated with Stat4 phosphorylation
and IFN-g production (35, 38). IL-12 responsiveness may,
however, also involve the activation of MAPKs that have
also been implicated in T cell receptor CD3/CD28–medi-
ated signaling. A 42–44-kD MAPK was found to be acti-
vated by IL-12 in mitogen-stimulated human T cells (39).
Interestingly, a more recent study showed that a p38
MAPK was activated by the synergistic action of IL-12 and
IL-2, and subsequently induced Stat1 and Stat3 phosphory-
lation on serine residues, which contributed to the IL-12–
induced functional effects (40). Moreover, inhibition of
p38 MAPK led to reduced IFN-g production in mouse
Th1 cells (41). In agreement with these recent reports, we
here show that inhibiting p38 MAPK by SB203580, as well
as inhibiting MEK1/2 by U0126, both significantly re-
duced IL-12–dependent IFN-g production in IL-12Rb1–
deficient T cells. In contrast, a second MEK1/2 inhibitor,
PD098059, had no inhibitory effect up to a concentration
of 25 mM. Since PD098059 blocks the activation of MEK,
but does not prohibit signaling by already activated MEK,
the failure of PD098059 to inhibit IL-12–induced IFN-g
production in IL-12R–deficient cells may suggest that pre-
activation of the TCC with anti-CD2/anti-CD28 leads to
activation of the MEK/ERK signaling pathway, which
subsequently integrates with signaling via p28 MAPK in
response to IL-12 to trigger IFN-g production. However,
future studies are required to unravel these signal transduc-
tion pathways and the putative cross-talk between various
pathways involved in IL-12 responsiveness in IL-12Rb1–
deficient cells.
Finally, it cannot be ruled out that other cell surface
molecules may associate with IL-12Rb2 and engage in
binding IL-12 and regulating IL-12 responsiveness. In one
study an 85-kD protein was found to be associated with the
IL-12Rb1 subunit and suggested to represent a hitherto
unidentified third component of the IL-12R complex (42).
The finding that all myc-responsive IL-12Rb1–deficient
TCCs appeared to be Th1 suggests significant Th1 cell de-
velopment in IL-12Rb1 deficiency. It is tempting to spec-
ulate that the residual IL-12 responsiveness shown in this
paper may play a role in Th1 differentiation in these pa-
tients, although we cannot exclude that this is regulated by
IL-12–independent mechanisms. Studies in IL-12p402/2
mice revealed polarized Th1 cell development in alloanti-
gen responses or during viral infections (43–45), suggesting
IL-12–independent pathways of Th1 induction. In hu-
mans, IL-12p40 protein deficiency was also found to be se-
lectively associated with curable, but not fatal, disseminat-
ing M.  bovis BCG and S. enteritidis infection (46). One
alternative IL-12–independent Th1 sensitizing pathway has
been shown to involve IFN-a. IFN-a, in humans, can di-
rectly induce Th1 development and induces IFN-g pro-
duction independently of IL-12 (47). IFN-a was also
found to synergize with IL-18 to induce IFN-g production
in human T cells (48). Here, we report normal responsive-
ness to IFN-a in IL-12Rb1–deficient patients based on
upregulated IL-12Rb2 expression and Stat4 activation.
In conclusion, in this study we show that IL-12Rb12/2
T cells can still develop into Th1 cells and can partially re-
spond to IL-12 by cellular proliferation and IFN-g produc-
tion. Although IL-12Rb2 can be expressed normally in the
absence of IL-12Rb1, this was most likely insufficient to
confer IL-12 responsiveness to these cells, as judged by the
lack of upregulation of Th1 cell surface markers and Stat4
activation. These results reveal a novel IL-12Rb1–inde-
pendent pathway of (residual) type 1 immunity in IL-
12Rb1 deficiency that may involve MAPK pathways.
Thus, human IL-12Rb1 deficiency provides a unique
model to uncover novel intracellular signaling pathways
and mechanisms involved in residual IFN-g production
and type 1 immunity.
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